Background: Liver disease and cirrhosis are common causes of mortality worldwide. Community-acquired pneumonia is recognized as a significant cause of morbidity and mortality in this population. There is lack of data showing outcomes or prognosis in patients with liver dysfunction who develop CAP. The objective of this study was to evaluate the clinical characteristics, incidence, and outcomes of hospitalized patients with CAP and liver disease.
Methods: This was a secondary analysis of the University of Louisville Pneumonia Study which was a prospective population-based cohort study of adults with community-acquired pneumonia. All patients were divided into three groups: 1)patients without liver disease, 2) patients with liver disease, and 3) patients with cirrhosis. Short and long-term outcomes were analyzed.
Results: Compared to patients without liver disease, we found no significant difference in time to clinical stability for patients with liver diseases (aHR: 1.01, 95% CI: 0.92 – 1.12; p=0.790), or cirrhosis (aHR: 0.85, 95% CI: 0.69 – 1.05; p=0.127). There were also no differences in median length of stay (LOS) between any two groups. Patients with cirrhosis had 35% higher risk of death at any time compared to patients with no liver disease (aHR: 1.35, 95% CI: 1.00-1.82; p=0.049), but did not have significantly increased risk compared to patients with liver disease (aHR: 1.37, 95% CI: 0.97 – 1.93, p=0.070).
Conclusions: In this study of hospitalized with CAP, patients with cirrhosis had significantly higher risk of death compared to patients without liver disease.
The author(s) received no specific funding for this work
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Karki, Bibodh Jung; Ponnekanti, Sravan K.; Salunkhe, Vidyulata; Tripathi, Nishita; Tella, Mahder A.; Furmanek, Stephen P.; and Arnold, Forest W.
"Outcomes of Patients Hospitalized with Community-Acquired Pneumonia with Liver Disease or Cirrhosis.,"
The University of Louisville Journal of Respiratory Infections: Vol. 4
, Article 3.
Available at: https://ir.library.louisville.edu/jri/vol4/iss2/3
Flow chart for three groups of study population are shown.
Figure 2. Kaplan-Meier curves for time to clinical stability for study population are shown.pdf (4 kB)
Kaplan-Meier curves for time to clinical stability for study population are shown
Figure 3. Kaplan Meier curve for Length of stay for study population are shown..pdf (4 kB)
Kaplan Meier curve for Length of stay for study population are shown.
Figure 4. Survival curve for study population are shown..pdf (8 kB)
Survival curve for study population are shown.